^(131)Ⅰ分子靶向治疗肝癌的新进展  

New Development of Iodine-131 in Molecular Targeted Therapy of Hepatocellular Carcinoma

作　　者：徐国厚[1] 杜明华[1] 

机构地区：[1]东南大学附属中大医院核医学科,南京210009

出　　处：《医学综述》2010年第19期2933-2935,共3页Medical Recapitulate

基　　金：东南大学国家自然科学基金预研项目(9290001412)

摘　　要：随着分子靶向药物的研发,放射核素碘-131(131Ⅰ)分子靶向治疗已成为原发性肝癌(HCC)治疗的研究热点。通过复习国内、外相关文献,总结131Ⅰ标记不同的耦联物靶向治疗HCC的临床研究与应用,表明131Ⅰ分子靶向治疗HCC具有较好的安全性和有效性。放射性核素131Ⅰ标记的耦联物也有了新的进展,如131Ⅰ可标记23-羟基白桦酸、单克隆抗体以及其他分子靶向治疗药物。但如何提高疗效及分子靶向性等问题仍有待解决。With the development of molecular targeted medicine,radionuclide iodine-131 in Molecular targeted therapy of hepatocellular carcinoma（HCC）has become a research hot spot recently.By reviewing domestic and foreign literature,to summarize the clinical researches and application of radionuclide iodine-131（131I）labeled different conjugates for targeted therapy of HCC,indicated that iodine-131 in molecular targeted therapy of HCC have a better security and validity.The radionuclide 131I labeled different conjugates also had a new progress,for example,131I may label 23-HBA,monoclonal antibody,as well as other molecular targeted medicine.But how to enhance the curative effect and molecular target tropism are still questions for solving.

关 键 词：肝癌 131碘 靶向治疗 23-羟基白桦酸 单克隆抗体 

分 类 号：R730.55[医药卫生—肿瘤]